The game is far from over. This setback is gut wrenching in the moment, but the company is not going under because of it; the research team will continue to produce elegant drugs, ponatinib will be widely adopted for most sufferers of CML over time, 113 will be acknowledged as being best in class for ALK fairly soon, and the stock price will rebound as investors with common sense realize that the warnings on the label will not prevent the widespread use of ponatinib in cases of recalcitrant CML for whatever reason, and eventually for GIST and other indications, I don't recall blood clots being focused on before now, and liver toxicity is a common side effect across all the drugs in this class, and for that matter, liver toxicity is a common side effect for many classes of drugs including statins and anti fungal meds among many others. Tests for liver toxicity are widely available and this issue can be dealt with by dosage adjustments and temporary discontinuance as necessary. Blood clots can be dealt with by blood thinners like plavix and coumadin and heparin among others. This drop was exacerbated by the macro issues including the fiscal cliff, and the tax selling ahead of the changes in the gains tax. On Monday I expect some further weakness from the weaker retailers who are despondent now and ready to throw in the towel. Most of the selling occurred Friday, and I expect either Monday pm or Tuesday that we see some rebound. For those of us in this for years, it is just one more disappointment but considering where we are now compared to December 2009 I am really not that upset, it has been a fantastic ride up and over the next three years this occurrence will be completely forgotten as the stock price will be a multiple of what it is now.
News 
Market Data 
Discover 
